Date: 20th May, 2023

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

Ref: Scrip Code No. 506260

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Change in Director.

Dear Sir/Madam.

Pursuant to Regulation 30(2) read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of the Company has at its meeting held on 19<sup>th</sup> May, 2023 appointed below mentioned directors:

1. Re-appointment of Dr. Mita Dixit (DIN 08198165) as a Non Executive, Independent Director.

Re-appointment of Dr. Mita Dixit (DIN 08198165) as a Non Executive, Independent Director for a Second term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;

2. Re-appointment of Mr. H. T. Patel (DIN 07342390) as a Non Executive, Independent Director.

Re-appointment of Mr. H. T. Patel (DIN 07342390) as a Non Executive, Independent Director for a Second term of 5 (Five) consecutive years effective from May 22<sup>nd</sup>, 2024 to 21<sup>st</sup> May, 2029;





3. Appointment of Mr. Arun L. Todarwal (DIN: 00020916) as a Non-Executive, Non-Independent, Chairman.

Appointment of Mr. Arun L. Todarwal (DIN: 00020916) as a Non-Executive, Non-Independent, Chairman of the Company with effect from 1st April, 2024 upon his ceasing to be the Non-Executive, Independent Director of the Company w.e.f. March 31<sup>st</sup>, 2024;

4. Appointment of Mr. Pradeep Thakur (DIN: 00685992) as an Additional Director (Non Executive, Independent Director).

Appointment of Mr. Pradeep Thakur (DIN: 00685992) as an Additional Director (Non Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;

5. Appointment of Mr. Siddharth Shah (DIN: 00004958) as an Additional Director (Non Executive, Independent Director).

Appointment of Mr. Siddharth Shah (DIN: 00004958) as an Additional Director (Non Executive, Independent Director) of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;

6. Appointment of Mr. Gaurav Shah (DIN: 02878186) as an Additional Director (Non Executive Director).

Appointment of Mr. Gaurav Shah (DIN: 02878186) as an Additional Director (Non Executive Director) of the Company w.e.f. July 1<sup>st</sup>, 2023.





Further, as per the requirement of the Circular No. List/Comp/14/2018-19 dated 20th June, 2018 issued by BSE on the subject of enforcement of SEBI Orders regarding appointment of Directors by listed companies we hereby affirm that the Director being appointed is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. ClR/CFD/CMD/4/2015 dated 9th September, 2015 are given in the enclosed Annexure-1.

Thanking you,

Yours faithfully,

For Anuh Pharma Ltd.

Hemant Auti Company Secretary & Compliance Officer





#### **ANNEXURE-1**

# BRIEF PROFILE OF DR. MITA C. DIXIT IS AS FOLLOWS:

Dr. Mita C. Dixit is a Chemical Engineer, Masters in Marketing Management, and PhD from BITS Pilani University. She is the first Indian to do a doctoral research in 'Conflict and Splits in Indian Family Businesses.' She is a Certified Management Consultant and a Corporate Director. She is a member of the Family Enterprise Research Consortium (USA), and a member of the Editorial Board, Journal of Amity Business School, India.

During the initial phase of her career, Mita worked with prominent corporates (Indian Express, Garwares, Piramal group) in marketing, branding, and product management functions. She was the Head - Research and Consultancy for the Centre for Family Managed Business at SPJIMR, Mumbai. As a Visiting faculty, she is associated with renowned management institutes offering family business programmes.

Relationships Between Directors - She is not related to any existing directors of the Anuh Pharma Limited.

### BRIEF PROFILE OF MR. H. T. PATEL IS AS FOLLOWS:

Mr. H. T. Patel, aged 68 years, is B Sc., ANSI (Sugar Technology), MBA by qualification. His DIN is 07342390. He has over 4 decades of varied experience, mainly in the pharmaceutical industry. He served as President API Business – Zydus Cadila in his last job. Before that he worked in Alembic Limited for 25 long years. He has discharged responsibilities in senior positions in reputed business groups with international operations. He is also a Director of Lewens Labs Private Limited Bharuch and Commercial Cooperative Bank Limited Vadodara.

He is on the Board of Management of Charusat University, Changa, Dist. Anand. He is a President and Managing Trustee of Yuvalay Charitable Trust, Vadodara and involved in many other social activities.

Relationships Between Directors - He is not related to any existing directors of the Anuh Pharma Limited.





# BRIEF PROFILE OF MR. ARUN TODARWAL IS AS FOLLOWS:

Mr. Arun Todarwal is a fellow member of the Institute of Chartered Accountants of India. He has been practicing as a Chartered Accountant since 1981. During his years of practice, he has handled various professional assignments including Statutory Audits, Internal Audits, Management and Systems Audits, Due diligences, Taxation, International Taxation, Joint Ventures, etc. He is well-versed in Tax matters and has travelled abroad on several occasions to deliver talks on Indian Taxation as well as Investment in India. Mr. Arun Todarwal is also a member of the Institute of Internal Auditors, National Centre for Quality Management, Bombay Management Association and Bombay Chartered Accountants Society. His vast experience has put him on panel of Auditors with the Registrar of Co-operatives Societies and the Official Liquidator, Mumbai High court.

### BRIEF PROFILE OF MR. PRADEEP THAKUR IS AS FOLLOWS:

Mr. Pradeep Thakur is a Post Graduate in Chemistry from Mumbai University and has Diploma in Export Management. He has studied "Masters in Administrative Management" at Jamnalal Bajaj Institute of Management studies, Mumbai. He has more than 30 years of working experience in Chemical and Pharmaceutical Industry in various functions like Process Development, Quality control, Quality Assurance, Business Development and General Administration. He has in the past worked with Bayer India, Anamed Instruments, Cipla Ltd, Dr. Reddy's Labs, Schweizerhall India and Aceto Pharma India Private Limited in various positions. His last assignment was with Aceto Pharma India Pvt. Limited as a Managing Director.

# BRIEF PROFILE OF MR. SIDDHARTH SHAH IS AS FOLLOWS:

Mr. Siddharth Shah holds a degree in Civil Engineering, Master in Business Administration and a Diploma in Securities Law. He has been on the Board of Directors of various Market Infrastructure Companies such as Bombay Stock Exchange (BSE), Central Depositories Services Ltd. (CDSL) and BOI Shareholding Ltd (a JV between BSE and Bank of India).

He has a vast experience of nearly 33 years in the financial markets and numerous technology based platforms. He was instrumental in many landmark projects like





Online Trading platform of BSE, Demutualization and Corporatization of BSE, Listing of BSE, among others.

He held the leadership role as Chairman of BSE Brokers Forum (an Industry body of more than 1,000 brokers).

He is currently the CEO of his 3rd generation family run brokerage house dealing in various investment verticals.

# BRIEF PROFILE OF MR. GAURAV SHAH IS AS FOLLOWS:

"Mr. Gaurav Shah, age 42 years, has a Bachelor's Degree in Engineering from USA (Computers) & has completed Diploma in Family Managed Business Administration from NMIMS, Mumbai.

He has an experience of 19 years in the Pharmaceutical industry. Handling Formulations, APIs & Logistics businesses.

Currently he is involved in management of API & Logistics business of SK Group.

His specific area of interest is Marketing and Management."

The above appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to the approval of the Shareholders at the ensuing Annual General Meeting.

